American International Group Inc. boosted its position in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 2.3% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 98,358 shares of the biopharmaceutical company’s stock after buying an additional 2,242 shares during the period. American International Group Inc.’s holdings in Alexion Pharmaceuticals were worth $10,637,000 as of its most recent SEC filing.
Other large investors have also recently bought and sold shares of the company. BlackRock Inc. lifted its stake in shares of Alexion Pharmaceuticals by 1.2% during the second quarter. BlackRock Inc. now owns 16,225,615 shares of the biopharmaceutical company’s stock worth $2,125,230,000 after buying an additional 199,298 shares during the period. NuWave Investment Management LLC raised its stake in Alexion Pharmaceuticals by 1,996.4% in the 3rd quarter. NuWave Investment Management LLC now owns 587 shares of the biopharmaceutical company’s stock worth $58,000 after acquiring an additional 559 shares during the last quarter. DNB Asset Management AS raised its stake in Alexion Pharmaceuticals by 4.9% in the 3rd quarter. DNB Asset Management AS now owns 47,485 shares of the biopharmaceutical company’s stock worth $4,651,000 after acquiring an additional 2,216 shares during the last quarter. Sumitomo Mitsui DS Asset Management Company Ltd lifted its position in Alexion Pharmaceuticals by 16.1% during the 3rd quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 13,860 shares of the biopharmaceutical company’s stock worth $1,357,000 after acquiring an additional 1,927 shares during the period. Finally, Campbell & CO Investment Adviser LLC lifted its position in Alexion Pharmaceuticals by 52.3% during the 3rd quarter. Campbell & CO Investment Adviser LLC now owns 3,073 shares of the biopharmaceutical company’s stock worth $301,000 after acquiring an additional 1,055 shares during the period. Hedge funds and other institutional investors own 91.35% of the company’s stock.
A number of brokerages have recently weighed in on ALXN. Cowen reissued a “buy” rating and issued a $165.00 price objective on shares of Alexion Pharmaceuticals in a report on Thursday, January 30th. BidaskClub cut Alexion Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, January 22nd. Evercore ISI reaffirmed a “buy” rating and set a $145.00 target price on shares of Alexion Pharmaceuticals in a report on Sunday, November 17th. Nomura dropped their target price on Alexion Pharmaceuticals from $165.00 to $133.00 and set a “buy” rating on the stock in a research report on Monday, February 3rd. Finally, Robert W. Baird cut their price target on shares of Alexion Pharmaceuticals from $165.00 to $140.00 and set an “outperform” rating on the stock in a report on Friday, January 31st. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and sixteen have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $149.80.
Shares of ALXN opened at $102.56 on Friday. The company has a market capitalization of $22.71 billion, a price-to-earnings ratio of 9.56, a PEG ratio of 0.87 and a beta of 1.68. Alexion Pharmaceuticals, Inc. has a 52 week low of $94.59 and a 52 week high of $141.86. The stock’s 50-day moving average price is $106.86 and its 200-day moving average price is $107.37. The company has a quick ratio of 3.73, a current ratio of 4.25 and a debt-to-equity ratio of 0.23.
Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its quarterly earnings results on Thursday, January 30th. The biopharmaceutical company reported $2.71 earnings per share for the quarter, beating the consensus estimate of $2.60 by $0.11. Alexion Pharmaceuticals had a return on equity of 21.29% and a net margin of 48.17%. The company had revenue of $1.38 billion during the quarter, compared to analysts’ expectations of $1.32 billion. During the same period last year, the business earned $2.14 earnings per share. Alexion Pharmaceuticals’s quarterly revenue was up 22.7% on a year-over-year basis. As a group, equities analysts anticipate that Alexion Pharmaceuticals, Inc. will post 9.18 EPS for the current fiscal year.
About Alexion Pharmaceuticals
Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis.
Featured Story: Penny Stocks
Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).
Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.